Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inovio Pharma (INO)

Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 120,781
  • Shares Outstanding, K 66,730
  • Annual Sales, $ 220 K
  • Annual Income, $ -107,250 K
  • EBIT $ -96 M
  • EBITDA $ -93 M
  • 60-Month Beta 1.72
  • Price/Sales 385.92
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 201.55% (+40.78%)
  • Historical Volatility 49.09%
  • IV Percentile 45%
  • IV Rank 16.11%
  • IV High 908.26% on 08/07/25
  • IV Low 65.86% on 05/05/25
  • Expected Move (DTE 5) 0.3060 (16.91%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 849
  • Volume Avg (30-Day) 1,031
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 23,155
  • Open Int (30-Day) 28,263
  • Expected Range 1.5040 to 2.1160

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 3
  • High Estimate -0.36
  • Low Estimate -0.38
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +46.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4900 +21.48%
on 01/28/26
2.0300 -10.84%
on 02/24/26
+0.2800 (+18.30%)
since 01/27/26
3-Month
1.4700 +23.13%
on 01/20/26
2.7200 -33.46%
on 12/17/25
-0.1500 (-7.65%)
since 11/26/25
52-Week
1.3000 +39.23%
on 07/15/25
2.9789 -39.24%
on 09/09/25
-0.1300 (-6.70%)
since 02/27/25

Most Recent Stories

More News
INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options

INO : 1.8100 (+1.12%)
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit

NEW YORK , Feb. 26, 2026 /PRNewswire/ -- 

INO : 1.8100 (+1.12%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO

NEW YORK , Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO) and certain...

INO : 1.8100 (+1.12%)
Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , Feb. 26, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

INO : 1.8100 (+1.12%)
Inovio Pharmaceuticals, Inc. Stock Alert: INO Stockholders Who Lost Money in the Company Should Contact Robbins LLP for Information on How to Recover Their Losses

SAN DIEGO , Feb. 26, 2026 /PRNewswire/ -- Robbins LLP  reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals,...

INO : 1.8100 (+1.12%)
Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , Feb. 25, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: ...

INO : 1.8100 (+1.12%)
LEVI & KORSINSKY, LLP: SECTION 10(B) AND RULE 10B-5 CLAIMS ASSERTED IN INOVIO PHARMACEUTICALS SECURITIES LITIGATION

Shareholders Who Purchased INO Securities During Class Period Urged to Review Options

INO : 1.8100 (+1.12%)
Investors in Inovio Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 7, 2026 to Discuss Your Rights - INO

NEW YORK , Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO).

INO : 1.8100 (+1.12%)
Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO

LOS ANGELES , Feb. 23, 2026 /PRNewswire/ --  The DJS Law Group  reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. ("Inovio" or "the Company") (NASDAQ: INO ...

INO : 1.8100 (+1.12%)
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Feb. 23, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inovio Pharmaceuticals,...

INO : 1.8100 (+1.12%)

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

3rd Resistance Point 1.8933
2nd Resistance Point 1.8567
1st Resistance Point 1.8333
Last Price 1.8100
1st Support Level 1.7733
2nd Support Level 1.7367
3rd Support Level 1.7133

See More

52-Week High 2.9789
Fibonacci 61.8% 2.3376
Fibonacci 50% 2.1395
Fibonacci 38.2% 1.9413
Last Price 1.8100
52-Week Low 1.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar